Table 1.
The baseline characteristics and treatment regimen of the 12 patients enrolled
| PatientNo. | Diagnosis | Sex/age | HBsAg | HBeAg | HBVDNA | Pre-emptive therapy | Therapy /follow-up months | Medications |
|---|---|---|---|---|---|---|---|---|
| 1 | DM | M/41 | + | − | <103 | No | Pred/48 | Pred 50 mg qd, now reduce to 5 mg qd |
| 2 | DM | F/74 | − | − | Not done | No | Pred + AZA/16, died of cerebral infarction | Pred 50–20 mg qd + AZA 50 mg qd * 9 m |
| 3 | SLE | F/63 | + | + | 2.36 × 105 | ETV | Pred/45 | Pred 40 mg qd, now reduce to 5 mg qd |
| 4 | SCLE | F/49 | + | + | 1 × 107 | ETV | Pred/30 | Pred 50 mg qd, now reduce to 5 mg qd |
| 5 | AS | M/50 | + | − | <103 | No | SASP + MTX/34 | SASP 0.5 tid * 2 m MTX 10 mg qw * 24 m |
| 6 | AS | M/29 | + | − | 1.6 × 103 | No | SASP + MTX/44 | SASP 1.0 bid + MTX 10 mg qw * 6 m now SASP 1.0 bid * 26 m |
| 7 | AS | M/20 | + | + | 2.35 × 107 | No | SASP/48 | SASP 1.0 bid |
| 8 | RA | F/67 | + | + | 4.46 × 104 | No | MTX/47 | MTX 7.5 mg qw |
| 9 | AS | M/17 | + | − | <103 | No | SASP + MTX/47 | SASP 1.0 bid + MTX 5 mg qw * 3 m now withdraw |
| 10 | AS | M/24 | + | + | 2.43 × 105 | No | ETN/46 | ETN 25 mg qw * 3 m, 25 mg q2w * 2 m, 12.5 mg qm * 21 m |
| 11 | RA | F/44 | + | − | <103 | No | HCQ/LEF + ETN/44 | HCQ 0.2 bid + ETN 25 mg biw * 5 m |
| LEF 10 mg qn + ETN 25 mg qw * 2 m | ||||||||
| ETN 25 mg qw * 20 m | ||||||||
| 12 | AS | M/20 | + | + | Not done | No | SASP + ETN/43 | SASP 1.0 bid + ETN 25 mg biw * 3 m |
| Now withdraw |
AS ankylosing spondylitis, AZA azathioprine, DM dermatomyositis, ETN entanercept, ETV entecavir, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen, HBV hepatitis B virus, HCQ hydroxychloroquine, LEF leflunomide, MTX methotrexate, Pred prednisone, RA rheumatoid arthritis, SASP salazosulfapyridine, SCLE subacute cutaneous lupus erythematosus, SLE systemic lupus erythematosus